PMID- 36974007
OWN - NLM
STAT- MEDLINE
DCOM- 20230606
LR  - 20230609
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 201
IP  - 6
DP  - 2023 Jun
TI  - Pomalidomide and dexamethasone until progression after first salvage therapy in 
      multiple myeloma.
PG  - 1103-1115
LID - 10.1111/bjh.18772 [doi]
AB  - Lenalidomide maintenance in myeloma is well established. Nevertheless, 
      pomalidomide could provide an alternative. Myeloma patients in first relapse, 
      initially treated in the Intergroupe Francophone du Myelome (IFM) 2009 trial, and 
      subsequently in the IFM 2013-01 phase 2 trial, received four cycles of salvage 
      therapy with pomalidomide plus cyclophosphamide plus dexamethasone (PCD) with 
      transplantation plus 2 PCD consolidation or without transplantation but with 5 
      PCD and for all patients pomalidomide plus dexamethasone maintenance therapy. 
      This consisted of 28-day cycles of pomalidomide 4 mg daily on days 1-21 and 
      dexamethasone 20 mg weekly until progression. The primary endpoint was an 
      improved response to treatment. A total of 75/100 patients reached therapy. The 
      median follow-up time was 73 months. The median duration of treatment was 
      23.7 months. One third of patients improved their response from the initiation of 
      treatment: 11%, 19% and 4% to a very good partial response, complete response or 
      stringent complete response respectively. The median progression-free survival 
      time was 33.2 months and the median overall survival time was not reached. Among 
      the 75 patients, the reasons for pomalidomide discontinuation were progressive 
      disease (54%), adverse events (AEs) (30%), investigator discretion (11%) and 
      consent withdrawal (5%). Grade (G) 3/4 haematological AEs included neutropenia 
      (51%) and lymphopenia (35%); G3/4 drug-related non-haematological AEs (>5%) 
      comprised 13% infections. Long-term administration of pomalidomide and 
      dexamethasone is feasible and one third of the patients improved their response.
CI  - (c) 2023 The Authors. British Journal of Haematology published by British Society 
      for Haematology and John Wiley & Sons Ltd.
FAU - Garderet, Laurent
AU  - Garderet L
AUID- ORCID: 0000-0002-6138-8112
AD  - INSERM, UMR_S 938, Proliferation and Differentiation of Stem Cells, Paris, 
      France.
AD  - Departement d'Hematologie, AP-HP, Hopital Pitie Salpetriere, Paris, France.
AD  - Sorbonne Universite, Paris, France.
FAU - Kuhnowski, Frederique
AU  - Kuhnowski F
AD  - Institut Curie, Paris, France.
FAU - Berge, Benoit
AU  - Berge B
AD  - Euraxi, Joue-les-Tours, France.
FAU - Roussel, Murielle
AU  - Roussel M
AD  - Centre Hospitalier Universitaire, Limoges, France.
FAU - Devlamynck, Laure
AU  - Devlamynck L
AD  - Departement Statistique, Centre Hospitalier Universitaire, Toulouse, France.
FAU - Petillon, Marie Odile
AU  - Petillon MO
AD  - Maladies du Sang, Hopital Claude Huriez, CHRU Lille, Lille, France.
FAU - Escoffre-Barbe, Martine
AU  - Escoffre-Barbe M
AD  - Centre Hospitalier Universitaire, Rennes, France.
FAU - Lafon, Ingrid
AU  - Lafon I
AD  - Centre Hospitalier Universitaire, Dijon, France.
FAU - Facon, Thierry
AU  - Facon T
AD  - Maladies du Sang, Hopital Claude Huriez, CHRU Lille, Lille, France.
FAU - Leleu, Xavier
AU  - Leleu X
AUID- ORCID: 0000-0002-9822-4170
AD  - Centre Hospitalier Universitaire, Poitiers, France.
FAU - Karlin, Lionel
AU  - Karlin L
AD  - Hospices Civils de Lyon, Pierre Benite Cedex, France.
FAU - Perrot, Aurore
AU  - Perrot A
AD  - Service Hematologie CHU de Toulouse IUCT Oncopole, Toulouse, France.
FAU - Stoppa, Anne-Marie
AU  - Stoppa AM
AD  - Departement d'Hematologie, Institut Paoli Calmettes, Marseille, France.
FAU - Royer, Bruno
AU  - Royer B
AD  - Departement d'Immuno-Hematologie, Hopital Saint Louis, Paris, France.
AD  - Service d'Hematologie Clinique, Centre Hospitalier Universitaire, Amiens, France.
FAU - Chaleteix, Carine
AU  - Chaleteix C
AD  - Centre Hospitalier Universitaire, Clermont Ferrand, France.
FAU - Tiab, Mourad
AU  - Tiab M
AD  - Hopital de La Roche sur Yon, La Roche sur Yon, France.
FAU - Araujo, Carla
AU  - Araujo C
AD  - Centre Hospitalier de la Cote Basque, Bayonne, France.
FAU - Lenain, Pascal
AU  - Lenain P
AD  - Centre Henri Becquerel, Rouen, France.
FAU - Macro, Margaret
AU  - Macro M
AD  - Centre Hospitalier Universitaire, Caen, France.
FAU - Belhadj, Karim
AU  - Belhadj K
AUID- ORCID: 0000-0002-7455-5434
AD  - Centre Hospitalier Universitaire Henri Mondor, Creteil, France.
FAU - Ikhlef, Souhila
AU  - Ikhlef S
AD  - Service d'Hematologie, Hopital Saint Antoine, Paris, France.
FAU - Hulin, Cyrille
AU  - Hulin C
AD  - Centre Hospitalier Universitaire, Bordeaux, France.
FAU - Loiseau, Herve Avet
AU  - Loiseau HA
AD  - Service Hematologie CHU de Toulouse IUCT Oncopole, Toulouse, France.
FAU - Attal, Michel
AU  - Attal M
AD  - Service Hematologie CHU de Toulouse IUCT Oncopole, Toulouse, France.
FAU - Moreau, Philippe
AU  - Moreau P
AUID- ORCID: 0000-0003-1780-8746
AD  - Centre Hospitalier Universitaire Hotel Dieu, Nantes, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230327
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - D2UX06XLB5 (pomalidomide)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Humans
MH  - *Multiple Myeloma
MH  - Salvage Therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Dexamethasone
OTO - NOTNLM
OT  - maintenance treatment
OT  - myeloma therapy
OT  - pomalidomide
EDAT- 2023/03/29 06:00
MHDA- 2023/06/06 06:42
CRDT- 2023/03/28 01:42
PHST- 2023/03/09 00:00 [revised]
PHST- 2022/11/20 00:00 [received]
PHST- 2023/03/14 00:00 [accepted]
PHST- 2023/06/06 06:42 [medline]
PHST- 2023/03/29 06:00 [pubmed]
PHST- 2023/03/28 01:42 [entrez]
AID - 10.1111/bjh.18772 [doi]
PST - ppublish
SO  - Br J Haematol. 2023 Jun;201(6):1103-1115. doi: 10.1111/bjh.18772. Epub 2023 Mar 
      27.